These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34969427)

  • 1. How much does TB screening cost? A systematic review of economic evaluations.
    Empringham B; Alsdurf H; Miller C; Zwerling A
    Int J Tuberc Lung Dis; 2022 Jan; 26(1):38-43. PubMed ID: 34969427
    [No Abstract]   [Full Text] [Related]  

  • 2. Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review.
    Alsdurf H; Empringham B; Miller C; Zwerling A
    BMC Infect Dis; 2021 Sep; 21(1):935. PubMed ID: 34496804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
    Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
    JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
    Fitzpatrick C; Floyd K
    Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for pulmonary tuberculosis in high-risk groups of diabetic patients.
    Ji Y; Cao H; Liu Q; Li Z; Song H; Xu D; Tian D; Qiu B; Wang J
    Int J Infect Dis; 2020 Apr; 93():84-89. PubMed ID: 31978585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted screening and treatment for latent tuberculosis infection using QuantiFERON-TB Gold is cost-effective in Mexico.
    Burgos JL; Kahn JG; Strathdee SA; Valencia-Mendoza A; Bautista-Arredondo S; Laniado-Laborin R; Castañeda R; Deiss R; Garfein RS
    Int J Tuberc Lung Dis; 2009 Aug; 13(8):962-8. PubMed ID: 19723375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Screening Strategy for Latent Tuberculosis Infection (LTBI) in Contacts of Tuberculosis Patients: Systematic Review and Quality Assessment.
    Yoopetch P; Chitpim N; Jittikoon J; Udomsinprasert W; Thavorncharoensap M; Youngkong S; Praditsitthikorn N; Mahasirimongkol S; Chaikledkaew U
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru.
    Shah L; Rojas M; Mori O; Zamudio C; Kaufman JS; Otero L; Gotuzzo E; Seas C; Brewer TF
    Epidemiol Infect; 2017 Apr; 145(6):1107-1117. PubMed ID: 28162099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microscopic observation drug-susceptibility assay vs. Xpert
    Wikman-Jorgensen PE; Llenas-García J; Pérez-Porcuna TM; Hobbins M; Ehmer J; Mussa MA; Ascaso C
    Trop Med Int Health; 2017 Jun; 22(6):734-743. PubMed ID: 28380276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries.
    Jo Y; Gomes I; Flack J; Salazar-Austin N; Churchyard G; Chaisson RE; Dowdy DW
    EClinicalMedicine; 2021 Jan; 31():100707. PubMed ID: 33554088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India.
    Azman AS; Golub JE; Dowdy DW
    BMC Med; 2014 Oct; 12():216. PubMed ID: 25358459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations.
    Diel R; Lampenius N; Nienhaus A
    Pharmacoeconomics; 2015 Aug; 33(8):783-809. PubMed ID: 25774015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.
    Sun D; Dorman S; Shah M; Manabe YC; Moodley VM; Nicol MP; Dowdy DW
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):552-8. PubMed ID: 23485389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted.
    Neumann PJ; Thorat T; Zhong Y; Anderson J; Farquhar M; Salem M; Sandberg E; Saret CJ; Wilkinson C; Cohen JT
    PLoS One; 2016; 11(12):e0168512. PubMed ID: 28005986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia.
    Jo Y; Kagujje M; Johnson K; Dowdy D; Hangoma P; Chiliukutu L; Muyoyeta M; Sohn H
    PLoS One; 2021; 16(9):e0256531. PubMed ID: 34499668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.